OSI Pharmaceuticals, Inc. (OSIP) - Financial and Strategic Analysis Review

Document Sample
OSI Pharmaceuticals, Inc. (OSIP) - Financial and Strategic Analysis Review Powered By Docstoc
					            OSI Pharmaceuticals, Inc. (OSIP) - Financial and Strategic Analysis
                                         Review

       Reference Code: GDPH32029FSA                                                                                        Publication Date: JUL 2010

       41 Pinelawn Road                      Phone            +1 631 9622000                       Revenue           428.2 (million USD)
       Melville, NY                          Fax                                                   Net Profit        75.93 (million USD)
       11747                                 Website          www.osip.com                         Employees         512
       United States                         Exchange         OSIP [NASDAQ]                        Industry          Pharmaceuticals & Healthcare

      Company Overview
       OSI Pharmaceuticals, Inc. (OSI) is a biopharmaceutical company focused on the discovery, development and commercialization
       of innovative molecular targeted therapies related to major therapeutic areas such as oncology, diabetes and obesity. The
       company’s flagship product is Tarceva, a small molecule inhibitor of the epidermal growth factor receptor (EGFR) in the Oncology
       segment. The company is headquartered at Melville in New York, the US.

      Key Executives                                                                 SWOT Analysis
                      Name                                  Title                    OSI Pharmaceuticals, Inc., SWOT Analysis
       Robert A. Ingram                     Chairman                                 Strengths                    Weaknesses

       Colin Goddard                        Chief Executive Officer
                                                                                     Focus on Oncology                   Dependence on Third Party
       Santo J. Costa                       Director                                                                     Suppliers
       Kenneth B. Lee                       Director                                 Sturdy Research and
                                                                                     Development Activities              Limited Marketing Capability
       Viren Mehta                          Director
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData
                                                                                     Opportunities                       Threats
      Share Data
       OSI Pharmaceuticals, Inc.                                                     Product Pipeline                    Competitive Market
       Share Price (USD) as on 08-Jun-2010                                57.50
                                                                           1.29      Focus on Partnerships               Tightening of FDA’s
       EPS (USD)
                                                                                                                         Regulatory Oversight
       Market Cap (million USD)                                           3,519

       Enterprise Value (million USD)                                     3,631

       Shares Outstanding (million)                                             61   Source: Annual Report, Company Website, Primary and Secondary Research
       Source: Annual Report, Company Website, Primary and Secondary Research        GlobalData
       GlobalData

      Financial Performance                                                          Recent Developments
                                                                                     Apr 19, 2010       OSI Pharma Gets FDA Nod For Tarceva
                                             
				
DOCUMENT INFO
Description: OSI Pharmaceuticals, Inc. (OSI) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative molecular targeted therapies related to major therapeutic areas such as oncology, diabetes and obesity. The company’s flagship product is Tarceva, a small molecule inhibitor of the epidermal growth factor receptor (EGFR) in the Oncology segment. The company is headquartered at Melville in New York, the US. OSI Pharmaceuticals, Inc. Key Recent Developments Apr 19, 2010 OSI Pharma Gets FDA Nod For Tarceva Mar 19, 2010 Astellas Announces Changes To Director Nominees For Election To OSI's Board Of Directors Mar 01, 2010 Astellas Launches Hostile Bid To Acquire OSI Pharma Feb 23, 2010 OSI Pharmaceuticals Reports Net Income Of $75.9 Million In 2009 Jan 28, 2010 Novella, OSI Pharmaceuticals To Expand Clinical Service Agreement This comprehensive SWOT profile of OSI Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including, - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.